These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Amplification of the MYCN oncogene and deletion of putative tumour suppressor gene in human neuroblastomas. Schwab M Brain Pathol; 1990 Sep; 1(1):41-6. PubMed ID: 1669692 [TBL] [Abstract][Full Text] [Related]
23. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980 [TBL] [Abstract][Full Text] [Related]
24. Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization. Stock C; Bozsaky E; Watzinger F; Poetschger U; Orel L; Lion T; Kowalska A; Ambros PF Am J Pathol; 2008 Jan; 172(1):203-14. PubMed ID: 18165268 [TBL] [Abstract][Full Text] [Related]
25. Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo. VanDevanter DR; Piaskowski VD; Casper JT; Douglass EC; Von Hoff DD J Natl Cancer Inst; 1990 Dec; 82(23):1815-21. PubMed ID: 2250296 [TBL] [Abstract][Full Text] [Related]
27. Two-dimensional DNA electrophoresis identifies novel CpG islands frequently coamplified with MYCN in neuroblastoma. Wimmer K; Zhu XX; Lamb BJ; Kuick R; Ambros P; Kovar H; Thoraval D; Elkahloun A; Meltzer P; Hanash SM Med Pediatr Oncol; 2001 Jan; 36(1):75-9. PubMed ID: 11464910 [TBL] [Abstract][Full Text] [Related]
28. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563 [TBL] [Abstract][Full Text] [Related]
29. Analysis of candidate gene co-amplification with MYCN in neuroblastoma. George RE; Kenyon R; McGuckin AG; Kohl N; Kogner P; Christiansen H; Pearson AD; Lunec J Eur J Cancer; 1997 Oct; 33(12):2037-42. PubMed ID: 9516849 [TBL] [Abstract][Full Text] [Related]
30. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Teitz T; Wei T; Liu D; Valentine V; Valentine M; Grenet J; Lahti JM; Kidd VJ Oncogene; 2002 Mar; 21(12):1848-58. PubMed ID: 11896617 [TBL] [Abstract][Full Text] [Related]
31. Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1. Spieker N; Beitsma M; Van Sluis P; Chan A; Caron H; Versteeg R Genes Chromosomes Cancer; 2001 Jun; 31(2):172-81. PubMed ID: 11319804 [TBL] [Abstract][Full Text] [Related]
32. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma. Amler LC; Schürmann J; Schwab M Genes Chromosomes Cancer; 1996 Feb; 15(2):134-7. PubMed ID: 8834178 [TBL] [Abstract][Full Text] [Related]
33. Amplification of a DEAD box gene (DDX1) with the MYCN gene in neuroblastomas as a result of cosegregation of sequences flanking the MYCN locus. Noguchi T; Akiyama K; Yokoyama M; Kanda N; Matsunaga T; Nishi Y Genes Chromosomes Cancer; 1996 Feb; 15(2):129-33. PubMed ID: 8834177 [TBL] [Abstract][Full Text] [Related]
34. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma. Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189 [TBL] [Abstract][Full Text] [Related]
35. Differential amplification, assembly, and relocation of multiple DNA sequences in human neuroblastomas and neuroblastoma cell lines. Shiloh Y; Shipley J; Brodeur GM; Bruns G; Korf B; Donlon T; Schreck RR; Seeger R; Sakai K; Latt SA Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3761-5. PubMed ID: 3858848 [TBL] [Abstract][Full Text] [Related]
36. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Spitz R; Hero B; Skowron M; Ernestus K; Berthold F Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958 [TBL] [Abstract][Full Text] [Related]
37. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma. Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568 [TBL] [Abstract][Full Text] [Related]
38. Rearrangement in the coding region of the MYCN gene in a subset of amplicons in a case of neuroblastoma with MYCN amplification. Chen B; Jhanwar SC; Ladanyi M Diagn Mol Pathol; 2001 Jun; 10(2):100-4. PubMed ID: 11385318 [TBL] [Abstract][Full Text] [Related]
39. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. Marrano P; Irwin MS; Thorner PS Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929 [TBL] [Abstract][Full Text] [Related]
40. Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP. Van Roy N; Forus A; Myklebost O; Cheng NC; Versteeg R; Speleman F Cancer Genet Cytogenet; 1995 Jul; 82(2):151-4. PubMed ID: 7664245 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]